{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:36:36Z","timestamp":1771914996164,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40120-022-00324-0","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T09:02:49Z","timestamp":1642842169000},"page":"385-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data"],"prefix":"10.1007","volume":"11","author":[{"given":"Izumi","family":"Kawachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Otaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"key":"324_CR1","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"324_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12883-019-1534-9","volume":"19","author":"I Kawachi","year":"2019","unstructured":"Kawachi I, Okamoto S, Sakamoto M, et al. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database. BMC Neurol. 2019;19:324. https:\/\/doi.org\/10.1186\/s12883-019-1534-9.","journal-title":"BMC Neurol"},{"key":"324_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen3.12299","volume":"7","author":"M Ogino","year":"2016","unstructured":"Ogino M, Kawachi I, Otake K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7:158\u201367. https:\/\/doi.org\/10.1111\/cen3.12299.","journal-title":"Clin Exp Neuroimmunol"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen3.12411","volume":"8","author":"M Ogino","year":"2017","unstructured":"Ogino M, Okamoto S, Ohta H, et al. Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. Clin Exp Neuroimmunol. 2017;8:318\u201326. https:\/\/doi.org\/10.1111\/cen3.12411.","journal-title":"Clin Exp Neuroimmunol"},{"key":"324_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2217\/nmt-2017-0047","volume":"8","author":"M Ogino","year":"2018","unstructured":"Ogino M, Shiozawa A, Ota H, Okamoto S, Hiroi S, Kawachi I. Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data. Neurodegener Dis Manag. 2018;8:97\u2013103. https:\/\/doi.org\/10.2217\/nmt-2017-0047.","journal-title":"Neurodegener Dis Manag"},{"key":"324_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s42979-021-00592-x","volume":"2","author":"IH Sarker","year":"2021","unstructured":"Sarker IH. Machine learning: algorithms, real-world applications and research directions. SN Comput Sci. 2021;2:160. https:\/\/doi.org\/10.1007\/s42979-021-00592-x.","journal-title":"SN Comput Sci"},{"key":"324_CR7","unstructured":"IBM Cloud Education. Unsupervised learning [Internet]. Chicago (USA): IBM Cloud Learn Hub; 2020 [updated 2021 Sept 21; cited 2021 Oct 17]. https:\/\/www.ibm.com\/cloud\/learn\/unsupervised-learning."},{"key":"324_CR8","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1185\/030079906X115621","volume":"22","author":"EQ Wu","year":"2006","unstructured":"Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. Development of a COPD severity score. Curr Med Res Opin. 2006;22:1679\u201387. https:\/\/doi.org\/10.1185\/030079906X115621.","journal-title":"Curr Med Res Opin"},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s100720070018","volume":"55","author":"M Ishii","year":"2012","unstructured":"Ishii M. DRG\/PPS and DPC\/PDPS as prospective payment systems. Jpn Med Assoc J. 2012;55:279\u201391. https:\/\/doi.org\/10.1007\/s100720070018.","journal-title":"Jpn Med Assoc J"},{"key":"324_CR10","unstructured":"Ministry of Health, Labor and Welfare. Statistical classification of diseases and cause of death 2013 [Internet]. Tokyo (JP): Ministry of Health, Labor and Welfare; 2015 [cited 2020 Dec 23]. http:\/\/www.mhlw.go.jp\/toukei\/sippei\/. Japanese."},{"key":"324_CR11","unstructured":"Multiple Sclerosis and Neuromyelitis Optica Guideline Development Committee. Guidelines for multiple sclerosis and neuromyelitis optica 2017]. Tokyo (JP): Igaku\u2010shoin; 2017. Japanese."},{"key":"324_CR12","unstructured":"Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects [Internet]. Tokyo (JP): Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare; 2014 [updated 2017; cited 2020 Dec 23]. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka\/0000153339.pdf. Japanese."},{"key":"324_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/brain\/awh714","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595\u2013605. https:\/\/doi.org\/10.1093\/brain\/awh714.","journal-title":"Brain"},{"key":"324_CR14","doi-asserted-by":"publisher","first-page":"S815","DOI":"10.1007\/s100720070018","volume":"21","author":"GC Ebers","year":"2000","unstructured":"Ebers GC. The natural history of multiple sclerosis. Neurol Sci. 2000;21:S815\u20137. https:\/\/doi.org\/10.1007\/s100720070018.","journal-title":"Neurol Sci"},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0022-510x(02)00426-4","volume":"206","author":"S Vukusic","year":"2003","unstructured":"Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206:135\u20137. https:\/\/doi.org\/10.1016\/s0022-510x(02)00426-4.","journal-title":"J Neurol Sci"},{"key":"324_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1177\/1352458513488230","volume":"19","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ, Colman S, O\u2019Leary B, Taylor BV, Simmons RD. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler. 2013;19:1640\u20136. https:\/\/doi.org\/10.1177\/1352458513488230.","journal-title":"Mult Scler"},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3111\/13696998.2015.1086362","volume":"19","author":"J Ruutiainen","year":"2016","unstructured":"Ruutiainen J, Viita AM, Hahl J, Sundell J, Nissinen H. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016;19:21\u201333. https:\/\/doi.org\/10.3111\/13696998.2015.1086362.","journal-title":"J Med Econ"},{"key":"324_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3111\/13696998.2013.807267","volume":"16","author":"K Karampampa","year":"2013","unstructured":"Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16:939\u201350. https:\/\/doi.org\/10.3111\/13696998.2013.807267.","journal-title":"J Med Econ"},{"key":"324_CR19","doi-asserted-by":"publisher","first-page":"749406","DOI":"10.3389\/fneur.2021.749406","volume":"12","author":"S Ashida","year":"2021","unstructured":"Ashida S, Ochi H, Hamatani M, et al. Radiological and laboratory features of multiple sclerosis patients with immunosuppressive therapy: a multicenter retrospective study in Japan. Front Neurol. 2021;12:749406. https:\/\/doi.org\/10.3389\/fneur.2021.749406.","journal-title":"Front Neurol"},{"key":"324_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21520","volume":"21","author":"GJ Melendez-Torres","year":"2017","unstructured":"Melendez-Torres GJ, Auguste P, Armoiry X, et al. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol Assess. 2017;21:1\u2013352. https:\/\/doi.org\/10.3310\/hta21520.","journal-title":"Health Technol Assess"},{"key":"324_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40263-015-0251-1","volume":"29","author":"BH Johnson","year":"2015","unstructured":"Johnson BH, Bonafede MM, Watson C. Platform therapy compared with natalizumab for multiple sclerosis: relapse rates and time to relapse among propensity score-matched US patients. CNS Drugs. 2015;29:503\u201310. https:\/\/doi.org\/10.1007\/s40263-015-0251-1.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"324_CR22","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.29399\/npa.23330","volume":"55","author":"BI Tiftik\u00e7io\u011flu","year":"2018","unstructured":"Tiftik\u00e7io\u011flu BI. Multiple Sclerosis Functional Composite (MSFC): scoring instructions. Noro Psikiyatr Ars. 2018;55(Suppl 1):S46\u20138. https:\/\/doi.org\/10.29399\/npa.23330.","journal-title":"Noro Psikiyatr Ars"},{"key":"324_CR23","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00324-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T16:25:23Z","timestamp":1645201523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00324-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00324-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,22]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}